Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorKNAUER, Nadezhda
dc.contributor.authorMESCHANINOVA, Mariya
dc.contributor.authorMUHAMMAD, Sajjad
dc.contributor.authorHANGGI, Daniel
dc.contributor.authorMAJORAL, Jean-Pierre
dc.contributor.authorKAHLERT, Ulf
dc.contributor.authorKOZLOV, Vladimir
hal.structure.identifierChimie et Biologie des Membranes et des Nanoobjets [CBMN]
dc.contributor.authorAPARTSIN, Evgeny
dc.date.accessioned2024-04-30T08:37:25Z
dc.date.available2024-04-30T08:37:25Z
dc.date.issued2023
dc.identifier.issn1999-4923en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/199522
dc.description.abstractEnGlioblastoma is a rapidly progressing tumor quite resistant to conventional treatment. These features are currently assigned to a self-sustaining population of glioblastoma stem cells. Anti-tumor stem cell therapy calls for a new means of treatment. In particular, microRNA-based treatment is a solution, which in turn requires specific carriers for intracellular delivery of functional oligonucleotides. Herein, we report a preclinical in vitro validation of antitumor activity of nanoformulations containing antitumor microRNA miR-34a and microRNA-21 synthetic inhibitor and polycationic phosphorus and carbosilane dendrimers. The testing was carried out in a panel of glioblastoma and glioma cell lines, glioblastoma stem-like cells and induced pluripotent stem cells. We have shown dendrimer-microRNA nanoformulations to induce cell death in a controllable manner, with cytotoxic effects being more pronounced in tumor cells than in non-tumor stem cells. Furthermore, nanoformulations affected the expression of proteins responsible for interactions between the tumor and its immune microenvironment: surface markers (PD-L1, TIM3, CD47) and IL-10. Our findings evidence the potential of dendrimer-based therapeutic constructions for the anti-tumor stem cell therapy worth further investigation.
dc.language.isoENen_US
dc.rights.urihttp://creativecommons.org/licenses/by/
dc.subject.enDendrimers
dc.subject.enMicroRNA
dc.subject.enNucleic acid therapeutics
dc.subject.en3D tumor models
dc.subject.enGlioblastoma
dc.subject.enTumor stem cells
dc.subject.enSurface markers
dc.subject.enNanomedicine
dc.title.enEffects of Dendrimer-microRNA Nanoformulations against Glioblastoma Stem Cells
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/pharmaceutics15030968en_US
dc.subject.halSciences du Vivant [q-bio]/Canceren_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]/Neurobiologieen_US
dc.subject.halSciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologieen_US
bordeaux.journalPharmaceuticsen_US
bordeaux.page968en_US
bordeaux.volume15en_US
bordeaux.hal.laboratoriesCBMN : Chimie & de Biologie des Membranes & des Nano-objets - UMR 5248en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionBordeaux INPen_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierhal-04174917
hal.version1
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pharmaceutics&rft.date=2023&rft.volume=15&rft.issue=3&rft.spage=968&rft.epage=968&rft.eissn=1999-4923&rft.issn=1999-4923&rft.au=KNAUER,%20Nadezhda&MESCHANINOVA,%20Mariya&MUHAMMAD,%20Sajjad&HANGGI,%20Daniel&MAJORAL,%20Jean-Pierre&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée